Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years-Reference-Cited by-同舟云学术

Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years

Published:2019-02-13 Issue:6 Volume:104 Page:2443-2452
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Watts Nelson B¹^ORCID,Grbic John T²,Binkley Neil³,Papapoulos Socrates⁴,Butler Peter W⁵,Yin Xiang⁶,Tierney Antoniette⁷,Wagman Rachel B⁵,McClung Michael⁸⁹

Affiliation:

1. Osteoporosis and Bone Health Services Division, Mercy Health, Cincinnati, Ohio

2. Division of Foundational Sciences, Columbia University College of Dental Medicine, New York, New York

3. Divisions of Geriatrics and Endocrinology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

4. Center for Bone Quality, Leiden University Medical Center, Leiden, Netherlands

5. Global Development, Amgen Inc., Thousand Oaks, California

6. Global Biostatistical Science, Amgen Inc., Thousand Oaks, California

7. Global Safety, Amgen Inc., Thousand Oaks, California

8. Oregon Osteoporosis Center, Portland, Oregon

9. Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia

Funder

Amgen

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/104/6/2443/28574076/jc.2018-01965.pdf

Reference25 articles.

1. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic;Marx;J Oral Maxillofac Surg,2003

2. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study;Fizazi;Lancet,2011

3. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma;Henry;J Clin Oncol,2011

4. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program;Grbic;J Am Dent Assoc,2010

5. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension;Bone;Lancet Diabetes Endocrinol,2017

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Medication-Related Osteonecrosis of the Jaw;Dental Clinics of North America;2024-01

2. Biologic Antiresorptive: Denosumab;Indian Journal of Orthopaedics;2023-12

3. Update Diagnostik und Therapie der Osteoporose 2023;Journal für Gynäkologische Endokrinologie/Schweiz;2023-11-23

4. Medication-related Osteonecrosis of the Jaw Induced by Regenerative Therapy in Implant Dentistry: A Scoping Review;Journal of Dentistry;2023-11

5. Anti-resorptive therapy in the osteometabolic patient affected by periodontitis. A joint position paper of the Italian Society of Orthopaedics and Traumatology (SIOT) and the Italian Society of Periodontology and Implantology (SIdP);Journal of Orthopaedics and Traumatology;2023-07-15